Adverse EventsThe most common Grade ≥ III adverse events in the trial were anemia and rash, which could impact patient outcomes.
Stock PerformanceThe stock is expected to remain range bound until pipeline assets are in-licensed and/or motixafortide generates additional favorable data in pancreatic cancer and/or gene therapy indications.
Trial EnrollmentFull enrollment in the Phase IIb trial of motixafortide in pancreatic ductal adenocarcinoma is not expected until 2027, and pancreatic cancer is a particularly intractable disease.